November 12, 2008
SPI awarded best presentation at the 16th Annual AMSCON/AMSUS meeting for it's clinical otoprotection work. Read more about AMSUS...

October 30, 2008
SPI invited to be a speaker at GTCBio's CNS Diseases Partnering and Deal-Making Summit.
Read More...

August 7, 2008
FDA Allows Phase 2 Study for Sound Pharmaceuticals' Novel Drug to Prevent Chemotherapy Induced Hearing Loss. Read More...

July 23, 2008
Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer. Read More...

July 21, 2008
Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product. Read More...

March 25, 2008
VentureWire Lifesciences story covers Sound Pharma's start of Ph-II clinical trials of SPI-1005 to prevent and treat noise induced hearing loss. Read more...

August 31, 2007
Neurotech Insights newsletter focuses on Hearing Loss and current R & D efforts of SPI (pg.14)...
Read More...

July 1, 2007
LA Times article on Otoprotection. Read More...

January 4, 2007
Sound Pharmaceuticals Announces the Successful Completion of its Phase I Clinical Trial for SPI-1005.
Read More...

October 13, 2006
Sound Pharmaceuticals supports the formation of the Neurotechnology Industry Organization (NIO) as a founding member. Read more...

July 7, 2006
USPTO issues Notice of Allowance for Novel Patent on Hair Cell Regeneration in the Inner Ear.
Read More...

June 21, 2006
Sound Pharmaceuticals interviewed by MIT Technology Review. Read more…

June 12, 2006
New Drug for Hearing Loss Enters Clinical Testing. Read More...

March 21, 2006
Sound Pharmaceuticals presents at Invest Northwest Life Sciences Conference.
Read More...

December 23, 2005
Sound Pharmaceuticals to receive DARPA grant from the DoD to develop novel regenerative therapies.
Read More...

September 27, 2005
SPI publishes review in October issue of Drug Discovery Today: "Compounds for the Prevention and Treatment of Noise-Induced Hearing Loss"...Read Article...

March 23, 2005
SPI wins Best in Show competition at European C21 Bioventures Conference in London...Read More...

March 3, 2005
Sound Pharmaceuticals demonstrates no interference with cisplatin anti-tumor activity in tumor models using combined oral formulation to prevent drug induced hearing loss...Read More...

Feb. 10, 2005
Learn more about pill for noise induced hearing loss as seen on KING-TV (Seattle Channel 5)...
Video (Windows Media format, broadband)
Video (Windows Media format, low bandwidth version)

Dec. 31, 2004
SPI closes seed round financing at $3 Million.

Nov. 12, 2004
Puget Sound Business Journal article highlights military support for SPI research...Read More...

Nov. 11, 2004
KCPQ (Seattle Channel 13) News - SPI to test pill for noise induced hearing loss...
Video (Windows Media format, broadband)
Video (Windows Media format, low bandwidth version)

Oct. 28, 2004
SPI invited to present at the Royal National Institute for the Deaf about the future of hearing loss treatments...Read More...

Oct. 7, 2004
Sound Pharmaceuticals invited to present at the National Conference on Biotechnology Ventures Meeting Oct. 25th-27th.

Sept. 7, 2004
SPI Validates Combined Oral Formulation to Prevent Drug Induced Hearing Loss...
Read More...

July 7, 2004
USPTO issues Notice of Allowance for Novel Hearing Loss Treatment Patent...Read More...

June 30, 2004
Sound Pharmaceuticals submits the first Investigational New Drug Application to the FDA involving an Oral Compound to Prevent Noise Induced Hearing Loss...Read More...

Feb. 24, 2004
SPI presents data on Chemoprotection Technology at the 27th annual meeting of the Association for Research in Otolaryngology....Read More...

Feb. 24, 2004
SPI Presents Results on Auditory Hair Cell Regeneration Technology...Read More...

Feb. 4, 2004
SPI Publishes Results on Oral Compound to Prevent Noise Induced Hearing Loss...Read more...

Oct. 6, 2003
SPI talks to the Wall Street Transcript...Read more...

Sept. 26, 2003
European Patent Office grants patent to SPI for inner ear disease...Read more...

Sept. 17, 2003
Sound Pharmaceuticals Validates Oral Compound to Prevent Noise Induced Hearing Loss... Read more...

Aug. 8, 2003
Sound Pharmaceuticals was the platinum sponsor of the Multidisciplinary Management of Ear Disease Meeting Jointly Sponsored by United States Army Medical Command and Otolaryngology-Head and Neck Surgery Madigan Army Medical Center, Tacoma, Washington.

June 23-24, 2003
SPI presents novel otoprotection data at National Occupational Research
Agenda meeting in Washington, DC... Read more...

March 4, 2003
SPI selected to present at the 5th Annual Investment & Strategic Partnering Opportunities Conference... Read more...

Dec. 20, 2002
VentureWire Lifesciences runs article on "Sound Pharmaceuticals Sees $160K Phase I SBIR Grant" Read more...

Dec. 13, 2002
KomoTV (local ABC news affiliate) runs story on "New Pill Could Be Music To Your Ears -- Literally" Read More...

Nov. 15, 2002
Puget Sound Business Journal article "Biotech firm seeks treatment for hearing loss" Read More...

Oct. 2, 2002
SPI was informed that its SBIR phase I grant award entitled “Cellular Regeneration in the Organ of Corti” was approved by the NIH’s Division of Deafness and other Communication Disorders.

Sept. 4, 2002
SPI established its first Scientific Advisory Board with the following members: James M. Roberts, MD, PhD, at the Fred Hutchinson Cancer Research Center, Allen F. Ryan, PhD, at the University of California, San Diego, and Albrecht Wendel, PhD, at the University of Konstanz.

July 12, 2002
SPI acquired an exclusive worldwide license to patented p27Kip1 technology from the Fred Hutchinson Cancer Research Center in Seattle, WA, and Memorial Sloan Kettering Cancer Center in New York, NY for use in sensory system regeneration.

June 21, 2002
SPI acquired proprietary inner ear Regeneration Technology including pending patent applications from Otogene AG.

June 14, 2002
SPI completed its seed round of financing raising approximately $1M with participation from POSCO BioVentures located in Carlsbad, CA.

April 1, 2002
SPI initiates pre-clinical live animal testing of its lead compounds at the Institute for Systems Biology in Seattle, WA.

Feb. 1, 2002
SPI established its office and laboratories at 4010 Stone Way North in Seattle, WA to begin its R&D operations.